FDA 510(k) Premarket Notification

CLEARED

K242109 Xpert® Xpress CoV-2 plus (XPRS-COV2-10)

Jan 15, 2025
180 days to decision

K242109 · Product code: **QQX** · Microbiology
Source: https://www.510kdatabase.net/k242109/

SUBMISSION DETAILS

Decision	Substantially Equivalent (Cleared)
Submission type	Dual Track
Device classification	Respiratory Specimen Nucleic Acid Sars-cov-2 Test (QQX)
Date received	Jul 19, 2024
Decision date	Jan 15, 2025
Days to decision	180 days
Third-party review	No
Combination product	No
PCCP authorized	No
Summary / Statement	Summary

APPLICANT

Company	**Cepheid**
Location	Sunnyvale, CA, US
Contact	Suzette Chance
Website	https://www.cepheid.com
510(k) history	60 submissions · 57 cleared · 2006-2026

Cepheid is a molecular diagnostics company based in Sunnyvale, US. The company enables access to molecular diagnostic testing globally through its Xpert platform and related solutions. Cepheid has received FDA 510(k) clearances from total submissions since its first clearance in 2006. The company specializes in Microbiology devices, which represent 93% of its regulatory submissions. Its latest FDA 510(k) clearance in 2026 demonstrates continued active development and market presence. Recent cleared devices span respiratory diagnostics, infectious disease detection, antimi...